Relmada Therapeutics Announces Participation in the 2021 SVB Leerink Global Healthcare Conference

Rhea-AI Summary

Relmada Therapeutics, Inc. (Nasdaq: RLMD) announced that CEO Sergio Traversa will participate in a fireside chat at the 2021 SVB Leerink Global Healthcare Conference on February 25, 2021, at 3:40 p.m. ET. The event will be webcast live, with a replay available for 90 days. Relmada focuses on addressing central nervous system diseases, particularly major depressive disorder (MDD), with its lead program, REL-1017, in late-stage development as an adjunctive treatment for MDD in adults. The press release includes forward-looking statements regarding risks and uncertainties.

Positive

• Relmada's lead program, REL-1017, is in late-stage development for treating major depressive disorder.
• CEO Sergio Traversa's participation in a high-profile healthcare conference may enhance investor visibility.

Negative

• None.

NEW YORK, Feb. 23, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that Sergio Traversa, Chief Executive Officer of Relmada, will participate in a fireside chat at the 2021 SVB Leerink Global Healthcare Conference on Thursday, February 25, 2021 at 3:40 p.m. Eastern Time.

A live webcast of the fireside chat will be available by visiting the investors section of the Company's website at www.relmada.com.  The webcast will be available for replay for 90 days following the event.

About Relmada Therapeutics, Inc. 

Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD).  Our experienced and dedicated team is committed to making a difference in the lives of patients and their families.  Relmada' s lead program, REL-1017, is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission.  REL-1017 has entered late-stage development as an adjunctive treatment for MDD in adults.

Forward-Looking Statements

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by us or on our behalf. This press release contains statements which constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including but not limited to statements regarding the expected use of the proceeds from the offering. Any statement that is not historical in nature is a forward-looking statement and may be identified by the use of words and phrases such as "expects," "anticipates," "believes," "will," "will likely result," "will continue," "plans to," "potential," "promising," and similar expressions. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including the risk factors described under the heading "Risk Factors" set forth in the Company's reports filed with the SEC from time to time. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Readers are cautioned that it is not possible to predict or identify all the risks, uncertainties and other factors that may affect future results and that the risks described herein should not be a complete list.

Investor Contact: 
Tim McCarthy 
LifeSci Advisors 
212-915-2564 
tim@lifesciadvisors.com

Media Inquiries: 
FischTank PR
relmada@fischtankpr.com

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/relmada-therapeutics-announces-participation-in-the-2021-svb-leerink-global-healthcare-conference-301233488.html

SOURCE Relmada Therapeutics, Inc.

FAQ

What is the date and time of Relmada's presentation at the SVB Leerink Global Healthcare Conference?

Relmada's CEO Sergio Traversa will present on February 25, 2021, at 3:40 p.m. Eastern Time.

Where can I watch the webcast of Relmada's presentation?

The webcast will be available on Relmada's investor section of their website, with a replay for 90 days.

What is the focus of Relmada Therapeutics?

Relmada Therapeutics is focused on developing treatments for diseases of the central nervous system, particularly major depressive disorder.

What is REL-1017?

REL-1017 is Relmada's lead program, a novel NMDA receptor channel blocker in late-stage development for major depressive disorder.